{
    "clinical_study": {
        "@rank": "80473", 
        "arm_group": [
            {
                "arm_group_label": "1.2, continuous treatment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "1.2, non-continuous treatment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "2.4, non-continuous treatment", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to assess the safety of\n      long-term growth hormone treatment in growth-retarded children with intrauterine growth\n      retardation (IUGR) enrolled in trial GHRETARD/F/1/F."
        }, 
        "brief_title": "Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation", 
        "completion_date": {
            "#text": "April 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Foetal Growth Problem", 
            "Small for Gestational Age"
        ], 
        "condition_browse": {
            "mesh_term": "Fetal Growth Retardation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients born with IUGR enrolled in trial GHRETARD/F/1/F\n\n          -  Bone age below 14 years in boys and 12 years in girls\n\n        Exclusion Criteria:\n\n          -  Bone age above 14 years in boys and 12 years in girls"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "57", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01734447", 
            "org_study_id": "GHRETARD/F/2/F"
        }, 
        "intervention": [
            {
                "arm_group_label": "1.2, continuous treatment", 
                "description": "1.2 IU/kg/week, one injection per day, in six days out of seven days, for 12 months", 
                "intervention_name": "somatropin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "1.2, non-continuous treatment", 
                "description": "1.2 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months  (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)", 
                "intervention_name": "somatropin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2.4, non-continuous treatment", 
                "description": "2.4 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)", 
                "intervention_name": "somatropin", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 26, 2012", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France"
                }
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "3", 
        "official_title": "Discontinued Administration (6 Months a Year) of Growth Hormone to Children With Very Short Stature and Having Suffered From Intrauterine Growth Retardation: Safety and Effect on Growth of Long-term Therapy", 
        "overall_official": {
            "affiliation": "Novo Nordisk Pharmaceutique SAS", 
            "last_name": "Catherine Boisson-Lesage, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Glucose tolerance as assessed by hyperglycaemia induced by oral ingestion", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01734447"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Bone Age determined according to Greulich and Pyle method and measured on the left hand X-ray", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Pubertal development, assessed according to Tanner method", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Height velocity", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Final height", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Number of Adverse Events", 
                "safety_issue": "No"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2000", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}